Lophos Pharmaceuticals Submits Application for Controlled Drugs and Substances Dealer’s License
TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) — Lophos Holdings (The “Company”) is pleased to provide an update on its wholly owned subsidiary Lophos Pharmaceuticals (“Lophos”). Lophos is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). Lophos has made significant strides in launching operations at their recently acquired 10,000 square foot […]